| Title | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. | | Author(s) | Metz DC, Bochenek WJ, Pantoprazole US GERD Study Group | | Institution | Division of Gastroenterology, University of Pennsylvania Health System, 3400 Spruce Street, 3 Dulles, Philadelphia, PA 19104-4283, USA. david.metz@uphs.upenn.edu | | Source | Aliment Pharmacol Ther 2003 Jan; 17(1):155-64. | | MeSH | Adult
Aged
Aluminum Hydroxide
Anti-Ulcer Agents
Benzimidazoles
Double-Blind Method
Drug Combinations
Esophagitis
Female
Humans
Magnesium Hydroxide
Male
Middle Aged
Omeprazole
Ranitidine
Recurrence
Research Support, Non-U.S. Gov't
Silicic Acid
Sulfoxides
Treatment Outcome
| | Abstract | OBJECTIVES: To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis.
METHODS: Patients (371) were randomly assigned to receive pantoprazole 10, 20 or 40 mg or ranitidine 150 mg. Endoscopies were performed after 1, 3, 6 and 12 months or when symptoms suggesting relapse (grade = 2) developed. Gastric biopsies were obtained at baseline and on at least one postbaseline visit. Symptom-free days and Gelusil use were assessed.
RESULTS: Pantoprazole was significantly (P < 0.001) more effective in maintaining erosive oesophagitis healing. After 12 months, 33%, 40%, 68% and 82% of patients remained healed for the ranitidine and pantoprazole 10, 20 and 40 mg groups, respectively. Daytime and night-time heartburn were eliminated in > 90% of days for the pantoprazole 40 mg group. Gelusil use was significantly lower with pantoprazole 20 and 40 mg than with ranitidine (P < 0.02) during the first 9 months.
CONCLUSIONS: Twelve months of maintenance therapy with pantoprazole (10-40 mg once daily) was superior to ranitidine (150 mg twice daily) in maintaining erosive oesophagitis healing. Pantoprazole 40 mg provided the most consistent efficacy and was well tolerated. | | Language | eng | | Pub Type(s) | Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
| | PubMed ID | 12492745 |
|
